Efficacy and safety of aranoza-based therapy in neuroendocrine neoplasms. Prognostic role of O6-methylguanine DNA methyltransferase expression in tumor tissue
- Authors: Polozkova S.A.1, Gorbunova V.A1, Delektorskaya V.V1, Orel N.F1,2, Kozlov N.A1, Kuzminov A.E1, Markovich A.A1, Odintsova A.S1, Emelyanova G.S3, Stepanova E.V1, Kuznetsova A.A1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- Russian Medical Academy for Postgraduate Education
- A.I. Evdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 21, No 6 (2016)
- Pages: 293-299
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40295
- DOI: https://doi.org/10.18821/10289984-2016-21-6-293-299
- ID: 40295
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Svetlana A. Polozkova
N.N. Blokhin Russian Cancer Research Center
Email: elevana@list.ru
MD, Clinical Postgraduate of the Department of Chemotherapy Moscow, 115478, Russian Federation
V. A Gorbunova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
V. V Delektorskaya
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
N. F Orel
N.N. Blokhin Russian Cancer Research Center; Russian Medical Academy for Postgraduate EducationMoscow, 115478, Russian Federation
N. A Kozlov
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
A. E Kuzminov
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
A. A Markovich
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
A. S Odintsova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
G. S Emelyanova
A.I. Evdokimov Moscow State University of Medicine and DentistryMoscow, 127473, Russian Federation
E. V Stepanova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
A. A Kuznetsova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
References
- Kulke M., Siu L., Tepper J., Fisher G., Jaffe D., Haller D. et al. Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute, Neuroendocrine Tumor Clinical Trials Planning Meeting. J. Clin. Oncol. 2011; 29 (7): 934-43.
- Fjallskog M., Janson E., Falkmer U. et al. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology. 2008; 88: 53-8.
- Kouvaraki M., Ajani J., Hoff P., Wolff R., Evans D., Lozano R. et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. 2004; 22(23): 4762-71.
- Sarker D., Williams M., Hochhauser D. et al. 5-Fluorouracil, cisplatin and streptozocin (FCiSt): an effective new regimen for advanced pancreatic neuroendocrine tumours. In: ASCO Gastroin-testinal Cancers Symposium. 2004: Abstr. 100.
- Turner N., Strauss S., Sarker D. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumors. Br. J. Cancer. 2010; 102: 1106-12.
- Walter T., Bruneton D., Cassier P. et al. Evaluation of the combination 5-Fluorouracil, Dacarbazine, and Epirubicin in patients with advanced well-differentiated neuroendocrine tumors. Clin. Colorect. Cancer. 2010; 9(4): 248-54.
- Ekeblad S., Sundin A., Janson E. et al. Temozolomideas monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 2007; 13: 2986-91.
- Saif M., Kaley K., Brennan M. et al. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. Journal of Pancreas. 2013; 14(5): 498-501.
- Crona J., Fanola I., Lindholm D. et al. Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology. 2013; 98(2): 151-5.
- Fine R., Gulati A., Tsushima D. et al. Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors. J. Clin. Oncol. 2014; 32: Abstr. 179.
- Chan J., Stuart K., Earle C. et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2012; 30(24): 2963-8.
- Mitry E., Baudin E., Ducreux M. et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br. J. Cancer. 1999; 81(8): 1351-5.
- Муханов В.И., Платонова Г.Н., Перетолчина Н.М. и др. Новый противоопухолевый препарат Араноза. Химиотерапия опухолей в СССР. 1980; 32: 133-9.
- Liu L., Gerson S. Targeted modulation of MGMT: clinical implications. Clin. Cancer Res. 2006; 12: 328-31.
- Степанова Е.В., Абрамов М.Е., Барышников А.Ю., Личиницер М.Р. Алкилгуаниналкилтрансфераза как фактор предсказания эффективности режима дакарбазин + цисплатин + нидран у больных метастатической меланомой кожи. Саркомы костей, мягких тканей и опухоли кожи. 2011; (1): 50-4.
- Olsen I., Sorensen J., Federspiel B. et al. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. Scient. World J. 2012; 2012: 1-4.
- Welin S., Sorbye H., Sebjornsen S. et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011; 117: 4617-22.
- Olsen I., Knigge U. et al. Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomas. J. Canc. 2014; 5(8): 628-32.
- Kulke M., Hornick J., Frauenhoffer C. et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomidebased therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 2009; 15(1): 338-45.
- Hentic O., Cros J. et al. Methylguanin DNA Methyl Transferase (MGMT) expression predicts response to temozolomide in patients with digestive Neuroendocrine Tumors (NETs). In: 9th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine TumorDise ase. 7-9 march 2012: Abstracts. Copenhagen; 2012.
- Muller D., Rinke A., Krug S., Majumder M., Konig A., Gress T. Dacarbazine chemotherapy in pancreatic NET. Pancreatology. 2013; Abstr. O-29.
- Eriksson B., Öberg K. Neuroendocrine tumours of the pancreas. Br. J. Surg. 2000; 87(2): 129-31.